The founders of Zirus Inc. believe they can create an antiviral drug, possibly a potent, broad-spectrum one, by disrupting human cell components that viruses need, without adversely affecting the cell. To find human genes and their protein products vital to viruses, the Buford, GA-based start-up is leveraging technology for what it calls a "gene trap."
1384 Buford Business Boulevard
Buford, GA 30518
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.
Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?
GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut